🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. QTORIN 3.9% Rapamycin Anhydrous Gel

    PALVELLA THERAPEUTICS, INC.

    Microcystic Lymphatic Malformation

    phase 3 small molecule active

    1 trial

  2. QTORIN 3.9% rapamycin anhydrous gel

    PALVELLA THERAPEUTICS, INC.

    Pachyonychia Congenita

    phase 3 small molecule completed

    1 trial

  3. QVM149

    Grace Therapeutics

    Asthma

    phase 3 small molecule terminated

    1 trial

  4. R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  5. RADELUMIN 2000 MBq/ml solution injectable, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 2000 MBq/ml Injektionslösung, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 2000 MBq/mL solución inyectable, Radelumin 2000 MBq/ml oplossing voor injectie, RADELUMIN 2000 MBq/ml solution injectable, Radelumin 1300 MBq/ml Injektionslösung, Radelumin 1300 MBq/ml oplossing voor injectie, RADELUMIN 2000 MBq/ml solution injectable, RADELUMIN 1300 MBq/ml solution injectable, Radelumin 1300 MBq/mL solución inyect

    Advanced Accelerator Applications

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  6. RAP-219

    Rapport Therapeutics

    Focal Seizure

    phase 3 small molecule active

    2 trials

  7. REGN7508

    Regeneron UK Limited

    Peripheral Artery Disease (PAD)

    phase 3 small molecule active

    1 trial

  8. REL-1017

    RELMADA THERAPEUTICS, INC.

    Major Depressive Disorder

    phase 3 small molecule completed

    3 trials

  9. REN001

    OnKure Therapeutics

    Primary Mitochondrial Myopathy

    phase 3 small molecule terminated

    2 trials

  10. REX-001

    Lxo Ireland Designated Activity Company

    Peripheral Arterial Disease (PAD)

    phase 3 small molecule terminated

    2 trials

  11. RILUTEK 50 mg film-coated tablets, masitinib, Placebo to 200mg masitinib, masitinib, Riluzole Zentiva 50 mg film-coated tablets, Placebo to 100mg masitinib

    AB Science

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    1 trial

  12. RITUXIMAB, METHOTREXATE, MYCOPHENOLATE MOFETIL, RoActemra 162 mg solution for injection in pre-filled pen., AZATHIOPRINE, XELJANZ 5 mg film-coated tablets

    Pari Pharma GmbH

    Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.

    phase 3 small molecule active

    1 trial

  13. RLY-2608

    Relay Therapeutics

    PIK3CA Mutation

    phase 3 small molecule active

    2 trials

  14. RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  15. RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe, RO4893594

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  16. RO4893594, RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe

    Hoffmann-La Roche

    Neovascular age-related macular degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  17. RO7790121 Placebo, RO7790121

    Hoffmann-La Roche

    Moderately to Severely Active Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  18. RO7790121, RO7790121 Placebo

    Hoffmann-La Roche

    Moderately to Severely Active Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  19. RO7790121, RO7790121 Placebo

    Hoffmann-La Roche

    Moderately to Severely Active Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  20. RTX-GRT7039, Naropin® 5 mg/ml Injektionslösung

    Gruenenthal GmbH

    Moderate to severe pain associated with Osteoarthritis of the knee

    phase 3 small molecule active

    1 trial

  21. Radiotherapy

    International Peace Maternity and Child Health Hospital

    Cervix Cancer

    phase 3 other completed

    1 trial

  22. Ralinepag

    United Therapeutics Europe Ltd

    PAH

    phase 3 small molecule terminated

    2 trials

  23. Ralinepag, Ralinepag, Ralinepag, Ralinepag

    United Therapeutics Europe Ltd

    Pulmonary arterial hypertension (PAH)

    phase 3 small molecule active

    1 trial

  24. Raltegravir

    United Therapeutics Europe Ltd

    Human Immunodeficiency Virus

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources